EVAX announces EVX-01 biomarker presentation at SITC 2025

Rhea-AI Filing Summary

Evaxion A/S disclosed that it will present new biomarker data for its AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting. The Form 6-K furnishes a press release as Exhibit 99.1 and incorporates this report by reference into several of the company’s registration statements. The filing contains no financial results, trial endpoints, patient counts, or detailed data—only the announcement of the planned presentation. Investors are informed of the forthcoming scientific disclosure but must look to the press release or the SITC presentation itself for substantive clinical or biomarker findings.

Positive

• EVX-01 will have new biomarker data presented at SITC 2025
• Press release is furnished as Exhibit 99.1, ensuring formal disclosure to investors

Negative

• Filing contains no clinical data, patient counts, endpoints, or trial results
• No financial information or guidance is provided in this Form 6-K

Insights

Clinical R&D Analyst

Evaxion will disclose biomarker findings for its personalized cancer vaccine EVX-01 at SITC 2025.

The company announced a planned presentation of new biomarker data, which can affect clinical interpretation of EVX-01's mechanism or patient selection if the data are substantive. This filing furnishes the press release as Exhibit 99.1 and serves primarily as a notice to investors about the upcoming scientific disclosure.

If the presented biomarkers clarify responder profiles or correlate with clinical activity, that information could meaningfully influence investor assessment of the program; however, the Form 6-K itself contains no data, endpoints, or patient numbers, so material conclusions must await the actual presentation or the press release text.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On October 3, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits  

Exhibit No.		Description
99.1		Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: October 3, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What will Evaxion (EVAX) present at SITC 2025?

The company will present new biomarker data for its AI-designed personalized cancer vaccine EVX-01.

Does the Form 6-K include the EVX-01 biomarker data?

No. The Form 6-K furnishes a press release as Exhibit 99.1 announcing the presentation but does not include the underlying data.

Is the press release officially filed for investors to review?

Yes. The press release is furnished with the Form 6-K as Exhibit 99.1 and is incorporated by reference into certain registration statements.

Will this filing change Evaxion's financial guidance or results?

This Form 6-K contains no financial results or guidance; it only announces the planned scientific presentation.

Where can investors find the detailed biomarker results?

Investors should review the press release and materials from the SITC 2025 presentation for substantive results.